Answers are grounded in this paper and cite their sources.
Core-binding factor acute myeloid leukemia (CBF-AML), defined by RUNX1::RUNX1T1 or CBFB::MYH11 , is classified as favorable risk, yet clinical outcomes remain heterogeneous. Cooperating kinase mutations explain only part of this variability, prompting interest in adaptor proteins that regulate signaling intensity, duration, and cellular organization. This narrative review critically evaluates their biological and potential prognostic relevance, distinguishing observations in CBF-AML patients, fusion-relevant experimental models, and other leukemia contexts. CBL splice-site and exon 8/9 alterations link defective receptor attenuation to CBF-AML, while RUNX1::RUNX1T1-mediated regulation of LAT2 connects adaptor expression to differentiation. The germline SH2B3 rs111340708 variant has been associated with altered splicing in AML and shorter overall survival in an exploratory subgroup of 32 CBF-AML patients, without independent validation. GAB2 provides mechanistic links to KIT and FLT3 signaling, but functional dependence in CBF-AML remains unproven. Evidence for GRB10, DOK proteins, CRKL, and STAP2 is predominantly extrapolative. Together, these findings suggest that adaptor dysregulation acts as a broad mechanistic modifier that tunes the amplitude, duration, and cellular outcomes of cooperating oncogenic signaling lesions. Recent fusion-specific clinical studies and molecular measurable residual disease (MRD) frameworks define the benchmark against which adaptor biomarkers must be tested. No adaptor marker is sufficiently validated to guide CBF-AML risk assignment or treatment selection. Translation requires reproducible assays, independent fusion-specific validation, and evidence of added prognostic value beyond co-mutations, treatment, and MRD.
No takes yet. Share an insight, caveat, or question.
Beghini et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: